Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.43 |
| ▸ | BCR | P11274 | 3/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044497 | 0.86 | MLYCD (0.48) | ABL1BCRKMT2AMAPK14HDAC1 | |
| SCHEMBL22044486 | 0.83 | DDR1 (0.48) | ABL1BCRRIPK1 | |
| SCHEMBL22044027 | 0.79 | MET (0.42) | ABL1BCRLMNAL3MBTL1 | |
| SCHEMBL22043989 | 0.75 | HPGD (0.40) | HPGDLMNAKMT2ANPSR1L3MBTL1 | |
| SCHEMBL22044482 | 0.75 | HPGD (0.38) | RIPK1HPGDLMNAKMT2ANPSR1 | |
| SCHEMBL22044455 | 0.71 | HPGD (0.43) | HPGDLMNAKMT2ANPSR1L3MBTL1 | |
| SCHEMBL27931784 | 0.71 | L3MBTL1 (0.52) | LMNAKMT2ANPSR1L3MBTL1HDAC1 | |
| SCHEMBL22044102 | 0.70 | DDR1 (0.48) | ABL1BCRKMT2AMAPK14 | |
| SCHEMBL27913563 | 0.68 | DDR1 (0.47) | RIPK1LMNAKMT2ANPSR1L3MBTL1 | |
| SCHEMBL22044158 | 0.67 | ROCK2 (0.47) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | ABL1 297/4885BCR 181/4885RIPK1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.